Trial Profile

A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies or Lymphomas

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 02 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IBI 363 (Primary)
Indications Lymphoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors Innovent Biologics

Most Recent Events

18 Dec 2024 Planned End Date changed from 31 Aug 2024 to 31 Dec 2026.
18 Dec 2024 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2026.
19 May 2024 According to an Innovent Biologics media release, data from this trial will be presented at the upcoming medical conferences in June, including ESMO Virtual Plenary and ESMO Gastrointestinal Cancers Congress (ESMO GI) 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com